Toremifene citrate salt
SIGMA/T7204 - ≥98% (HPLC)
Synonym: (Z)
CAS Number: 89778-27-8
Empirical Formula (Hill Notation): C26H28ClNO · C6H8O7
Molecular Weight: 598.08
MDL Number: MFCD01729016
Linear Formula: C26H28ClNO · C6H8O7
Product Type: Chemical
assay | ≥98% (HPLC) |
color | white to off-white |
form | powder |
InChI | 1S/C26H28ClNO.C6H8O7/c1-2 |
InChI key | IWEQQRMGNVVKQW-OQKDUQJOSA |
Quality Level | 100 ![]() |
SMILES string | OC(=O)CC(O)(CC(O)=O)C(O)= |
solubility | DMSO: >10 mg/mL |
storage condition | desiccated |
storage temp. | 2-8°C |
Application: | Toremifene citrate salt has been used: • in cell-based ELISA • as a positive control to detect its antiviral activity against Ebola virus (EBOV) • to treat MCF7 and T47D breast cancer cell lines |
Biochem/physiol Actions: | Toremifene citrate is an oral selective estrogen receptor modulator (SERM). It is used in advanced (metastatic) breast cancer and being evaluated for prevention of prostate cancer. Toremifene citrate is known to increase bone mineral density in prostate cancer patients undergoing androgen deprivation therapy†. |
Features and Benefits: | This compound is featured on the Nuclear Receptors (Steroids) ![]() ![]() |
General description: | Toremifene is a triphenylethylene derivative. It exhibits antitumor and antiestrogen effects. Toremifene has estrogen-agonist effects on blood lipids and endometrium. |
Packaging: | 5, 25 mg in glass bottle |
Preparation Note: | Toremifene citrate salt is soluble in DMSO at a concentration that is greater than 10 mg/ml. |
Symbol | ![]() ![]() ![]() |
Signal word | Danger |
Hazard statements | H302 - H318 - H410 |
Precautionary statements | P273 - P280 - P301 + P312 + P330 - P305 + P351 + P338 + P310 |
Hazard Codes | Xn,N |
Risk Statements | 22-41-50/53 |
Safety Statements | 26-39-60-61 |
RIDADR | UN 3077 9 / PGIII |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
Purity | ≥98% (HPLC) |
Storage Temp. | 2-8°C |
UNSPSC | 51111800 |